Functional modulation of enterocytes by gram-positive and gram-negative microorganisms

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 286, Issue 4 49-4, 2004, Pages

  Otte, Jan Michel ^a   Podolsky, Daniel K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Escherichia coli Nissle 1917; Interleukin 8; Intestinal epithelial cell lines; Mucins; Probiotic mixture VSL 3; Probiotics; Transepithelial resistance; Zonula occludens 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; PROBIOTIC AGENT; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSKELETON; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INFECTION RESISTANCE; INTESTINE EPITHELIUM CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; SALMONELLA DUBLIN;

ESCHERICHIA COLI; SALMONELLA DUBLIN;

EID: 1642274741     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00341.2003     Document Type: Article

References (51)

1. Anderson JM and Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol Gastrointest Liver Physiol 269: G467-G475, 1995.
2. Becker PM, Verin AD, Booth MA, Liu F, Birukova A, and Garcia JG. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 281: L1500-L1511, 2001.
3. Bry L, Falk PG, Midtvedt T, and Gordon JI. A model of host-microbial interactions in an open mammalian ecosystem. Science 273: 1380-1383, 1996.
4. Campierei M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, and Gionchetti P. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs. mesalamine (Abstract). Gastroenterology 118: A4179, 2000.
5. Cario E and Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68: 7010-7017, 2000.
6. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, and Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 164: 966-972, 2000.
7. Clark MA, Hirst BH, and Jepson MA. Inoculum composition and Salmonella pathogenicity island I regulate M-cell invasion and epithelial destruction by Salmonella typhimurium. Infect Immun 66: 724-731, 1998.
8. Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA, Emerson SG, and Carding SR. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 160: 385-394, 1998.
9. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, and Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233, 1995.
10. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, and Owen MJ. T cell receptor-α β-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 150: 91-97, 1997.
11. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E, Nadel J, and Basbaum C. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1406: 251-259, 1998.
12. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, and Meyer Zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102: 448-455, 1995.
13. Fabia R, Ar'Rajab A, Johansson ML, Andersson R, Willen R, Jeppsson B, Molin G, and Bengmark S. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 54: 248-255, 1993.
14. Favier C, Neut C, Mizon C, Cortot A, Colombel JF, and Mizon J. Fecal β-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 42: 817-822, 1997.
15. Fuller R. Probiotics in man and animals. J Appl Bacteriol 66: 365-378, 1989.
16. Fuller R. Probiotics in human medicine. Gut 32: 439-442, 1991.
17. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, and Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309, 2000.
18. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, and Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209, 2003.
19. Hooper LV and Gordon JI. Commensal host-bacterial relationships in the gut. Science 292: 1115-1118, 2001.
20. Inohara N, Ogura Y, Chen FF, Muto A, and Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 276: 2551-2554, 2001.
21. Inohara N, Ogura Y, and Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 5: 76-80, 2002.
22. Jepson MA, Collares-Buzato CB, Clark MA, Hirst BH, and Simmons NL. Rapid disruption of epithelial barrier function by Salmonella typhimurium is associated with structural modification of intercellular junctions. Infect Immun 63: 356-359, 1995.
23. Jepson MA, Schlecht HB, and Collares-Buzato CB. Localization of dysfunctional tight junctions in Salmonella enterica serovar typhimurium-infected epithelial layers. Infect Immun 68: 7202-7208, 2000.
24. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, and Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853-858, 1997.
25. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, and Campieri M. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 97: 1182-1186, 2002.
26. Li JD, Dohrman AF, Gallup M, Miyata S, Gum JR, Kim YS, Nadel JA, Prince A, and Basbaum CB. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 94: 967-972, 1997.
27. Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, Bogatcheva N, Bottaro DP, and Garcia JG. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3β. FASEB J 16: 950-962, 2002.
28. Mack DR, Ahrne S, Hyde L, Wei S, and Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52: 827-833, 2003.
29. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, and Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365-375, 1996.
30. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, and Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116: 1107-1114, 1999.
31. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, and Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 5: 262-270, 1999.
32. Madsen KL. The use of probiotics in gastrointestinal disease. Can J Gastroenterol 15: 817-822, 2001.
33. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25: 653-658, 1997.
34. Malin M, Suomalainen H, Saxelin M, and Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40: 137-145, 1996.
35. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, and Jeppsson B. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 111: 334-344, 1996.
36. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
37. Medzhitov R, Preston-Hurlburt P, and Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997.
38. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, and Madara JL. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science 289: 1560-1563, 2000.
39. Onderdonk AB. Intestinal microflora and inflammatory bowel disease. In: Inflammatory Bowel Disease, edited by Kirsner JB. Philadelphia, PA: Saunders, 2000, p. 144-153.
40. Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, and Salminen SJ. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lactobacillus delbrueckii subsp bulgaricus. Lett Appl Microbiol 30: 10-13, 2000.
41. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, and Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639, 1999.
42. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, and Sartor RB. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8: 71-80, 2002.
43. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, and Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224-5231, 1998.
44. Steidler L. Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes Infect 3: 1157-1166, 2001.
45. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, and Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54, 2002.
46. Unno N, Menconi MJ, Smith M, Aguirre DE, and Fink MP. Hyper-permeability of intestinal epithelial monolayers is induced by NO: effect of low extracellular pH. Am J Physiol Gastrointest Liver Physiol 272: G923-G934, 1997.
47. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, and Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13: 1103-1108, 1999.
48. Xavier RJ and Podolsky DK. Microbiology: how to get along-friendly microbes in a hostile world. Science 289: 1483-1484, 2000.
49. Yan F and Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277: 50959-50965, 2002.
50. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, and Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 163: 1-5, 1999.
51. Zen Y, Harada K, Sasaki M, Tsuneyama K, Katayanagi K, Yamamoto Y, and Nakanuma Y. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol 161: 1475-1484, 2002.